… The main pharmacokinetic difference between short-acting (half-life of 2–5 h) and long-…
All GLP-1RAs have been found to cross the blood–brain barrier (BBB) and stimulate GLP-1 …

… are located outside of the blood–brain barrier suggesting that GLP-1 … The cells of the
blood–brain-barrier free AP can also be … These data indicate that the AP mediates central effects of …

… All of these observations strongly support that a main physiological action of endogenous …
Certain studies have discussed whether the agonists can cross the blood–brain barrier, which …

… Central nervous system (CNS) insulin must first cross the blood–brain barrier (BBB), a
specialized network of brain endothelial cells. This transport process is regulated by physiological …

… Role of the blood-brain barrier in the nutrition of the central … and soluble LRP in blood-brain
barrier Abeta clearance in Alz… Glucagon-like peptide-1 strengthens the barrier integrity in …

… central nervous system [3,4]. Interventions that would reduce aortic stiffness may delay memory
decline among … its analogues or agonists cross the blood-brain-barrier [51]—these were …

… the central nervous system. This review article discusses the potential antidepressant effects
of GLP-1RAs, especially in the context of their action on … the blood–brain barrier breakdown …

Aim We aimed to assess the effects of cerebral glucagon‐like peptide‐1 receptor (GLP‐1R)
activation on the glymphatic system and whether this effect was therapeutic for traumatic …

… effects in clinical trials in AD and PD patients. Studies show that growth factors and peptide
drugs that can cross the blood–brain barrier (… Again, the main problem for developing a drug …

… The NVU is the nexus between the cardiovascular and central nervous system (CNS). The
central component of the NVU is the blood-brain barrier (BBB) which consists of a monolayer …